Compare ACCL & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCL | NXTC |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 46.6M |
| IPO Year | 2025 | 2019 |
| Metric | ACCL | NXTC |
|---|---|---|
| Price | $3.10 | $13.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 82.0K | 37.2K |
| Earning Date | 02-20-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.91 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $4,888,824.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.11 | ★ N/A |
| Revenue Growth | ★ 11.91 | N/A |
| 52 Week Low | $2.10 | $2.69 |
| 52 Week High | $5.00 | $15.74 |
| Indicator | ACCL | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.16 |
| Support Level | N/A | $12.79 |
| Resistance Level | N/A | $14.65 |
| Average True Range (ATR) | 0.00 | 0.99 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 0.00 | 65.18 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.